Your browser doesn't support javascript.
loading
Choosing between medical management and liver transplant in urea cycle disorders: A conceptual framework for parental treatment decision-making in rare disease.
Gerstein, Maya T; Markus, Anne R; Gianattasio, Kan Z; Le Mons, Cynthia; Bartos, Janice; Stevens, David M; Mew, Nicholas Ah.
Afiliación
  • Gerstein MT; Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
  • Markus AR; Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
  • Gianattasio KZ; Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
  • Le Mons C; National Urea Cycle Disorders Foundation, Pasadena, California.
  • Bartos J; National Urea Cycle Disorders Foundation, Pasadena, California.
  • Stevens DM; Department of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
  • Mew NA; Rare Disease Institute, Children's National Health System, Washington, District of Columbia.
J Inherit Metab Dis ; 43(3): 438-458, 2020 05.
Article en En | MEDLINE | ID: mdl-31883128
ABSTRACT
Urea cycle disorders (UCD) are rare inherited metabolic disorders caused by deficiencies of enzymes and transporters required to convert neurotoxic ammonia into urea. These deficiencies cause elevated blood ammonia, which if untreated may result in death, but even with optimal medical management, often results in recurrent brain damage. There are two major treatments for UCD medical management or liver transplantation. Both are associated with mortality and morbidity but the evidence comparing outcomes is sparse. Thus, families face a dilemma should their child be managed medically, or should they undergo a liver transplant? To (a) describe the factors that contribute to treatment choice among parents of children diagnosed with UCD and to (b) organise these factors into a conceptual framework that reflects how these issues interrelate to shape the decision-making experience of this population. Utilising grounded theory, qualitative data were collected through semi-structured interviews with parents (N = 35) and providers (N = 26) of children diagnosed with UCD and parent focus groups (N = 19). Thematic content analysis and selective and axial coding were applied. The framework highlights the life-cycle catalysts that frame families' personal perceptions of risks and benefits and describes the clinical, personal, social, and system factors that drive treatment choice including disease severity, stability, and burden, independence, peer experiences, and cost, coverage and access to quality care. Findings equip providers with evidence upon which to prepare for productive patient interactions about treatment options. They also provide a foundation for the development of patient-centred outcome measures to better evaluate effectiveness of treatments in this population.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Padres / Conducta de Elección / Toma de Decisiones / Trastornos Innatos del Ciclo de la Urea Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: J Inherit Metab Dis Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Padres / Conducta de Elección / Toma de Decisiones / Trastornos Innatos del Ciclo de la Urea Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: J Inherit Metab Dis Año: 2020 Tipo del documento: Article